John Reed, J&J's incoming R&D chief (Sanofi)
February 13, 2023 05:08 PM ESTUpdated February 13, 07:58 PM
People
Bioregnum
R&D

John Reed lands in the top R&D post at J&J in his lat­est Big Phar­ma de­but

John Reed is on to his third act as a Big Phar­ma R&D chief.

The sci­en­tist with roots that run much deep­er than his stint as head of San­ford-Burn­ham has trad­ed in his job or­ches­trat­ing the pipeline at Sanofi in fa­vor of his new role as the top phar­ma de­vel­op­er at J&J, where he’s tak­ing the place of Math­ai Mam­men. His first act in Big Phar­ma came as Roche’s head of R&D at pRED, where he stepped in along­side the big shake­up that shut­tered its cam­pus in Nut­ley, NJ.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE
TRENDING NOW

As cash runs tight, blue­bird plunges af­ter pric­ing sick­le cell gene ther­a­py well above com­peti­tor and fail­ing to win ...

FDA ap­proves two gene ther­a­pies for sick­le cell dis­ease, in­clud­ing first that us­es CRISPR

The End­points 100 sur­vey: Has biotech hit rock bot­tom?

Bris­tol My­ers’ lead deal ne­go­tia­tor to de­part af­ter ink­ing se­ries of multi­bil­lion-dol­lar ac­qui­si­tions

Three big win­ners from Ab­b­Vie's $8.7B Cerev­el deal: A drug­mak­er, a CEO and a SPAC

sponsored

Ear­ly pre­dic­tion of out­comes in DL­B­CL clin­i­cal tri­als through MRD test­ing

A service from the Financial Times